A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,800
- 试验地点
- 536
- 主要终点
- Disease-Free Survival (DFS)
研究概览
简要总结
The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy.
The primary study hypothesis is that belzutifan plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The main inclusion and
排除标准
- •include but are not limited to the following:
- •Inclusion Criteria:
- •Has a histologically or cytologically confirmed diagnosis of RCC with clear cell component per American Joint Committee on Cancer (AJCC) (8th Edition), with or without sarcomatoid features
- •Has intermediate-high risk, high risk, or M1 no evidence of disease (NED) RCC as defined by the following pathological tumor-node metastasis and tumor grading:
- •Intermediate-high risk RCC: pT2, Grade 4 or sarcomatoid, N0, M0; pT3, any grade, N0, M0
- •High risk RCC: pT4, any Grade N0, M0; pT any stage, any Grade, N+, M0
- •M1 NED RCC participants who present not only with the primary kidney tumor but also solid, isolated, soft tissue metastases that can be completely resected at one of the following: the time of nephrectomy (synchronous) or, ≤2 years from nephrectomy (metachronous)
- •Has undergone complete resection of the primary tumor (partial or radical nephrectomy) and complete resection of solid, isolated, soft tissue metastatic lesion(s) in M1 NED participants
- •Must have undergone a nephrectomy and/or metastasectomy ≤12 weeks prior to randomization
- •Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 10 days before randomization.
- •Male participants must agree to continue contraception at least 7 days after the last dose of belzutifan/placebo
- •Female participants of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of pembrolizumab or at least 30 days after last dose of belzutifan/placebo, whichever occurs last
- •Has adequate organ function
- •Exclusion Criteria:
- •Has had a major surgery, other than nephrectomy plus resection of preexisting metastases for M1 NED participants, within 4 weeks prior to randomization
- •Has a pulse oximeter reading <92% at rest, requires intermittent supplemental oxygen, or requires chronic supplemental oxygen
- •Has clinically significant cardiovascular disease within 6 months from first dose of study intervention
- •Has other clinically significant disorders such as: serious active nonhealing wound/ulcer/bone fracture; requirement for hemodialysis or peritoneal dialysis
- •Has preexisting brain or bone metastatic lesions
- •Has received prior systemic therapy for RCC
- •Has received prior radiotherapy for RCC
- •Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention; administration of killed vaccines are allowed
- •Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
- •Has a known additional malignancy (other than RCC treated with nephrectomy and/or metastasectomy) that is progressing or has required active treatment within the past 3 years
- •Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs); replacement therapy is allowed
- •Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- •Has an active infection, requiring systemic therapy
- •Has a known history of human immunodeficiency virus (HIV) infection, a known history of Hepatitis B or known active Hepatitis C virus infection
- •Has had an allogenic tissue/solid organ transplant
研究组 & 干预措施
Placebo + Pembrolizumab
Participants receive placebo orally QD for up to approximately 54 weeks PLUS pembrolizumab 400 mg via IV infusion once Q6W for up to 9 administrations (up to approximately 54 weeks).
干预措施: Pembrolizumab (Biological)
Placebo + Pembrolizumab
Participants receive placebo orally QD for up to approximately 54 weeks PLUS pembrolizumab 400 mg via IV infusion once Q6W for up to 9 administrations (up to approximately 54 weeks).
干预措施: Placebo (Drug)
Belzutifan + Pembrolizumab
Participants receive belzutifan 120 mg orally once daily (QD) for up to approximately 54 weeks PLUS pembrolizumab 400 mg via intravenous (IV) infusion once every 6 weeks (Q6W) for up to 9 administrations (up to approximately 54 weeks).
干预措施: Pembrolizumab (Biological)
Belzutifan + Pembrolizumab
Participants receive belzutifan 120 mg orally once daily (QD) for up to approximately 54 weeks PLUS pembrolizumab 400 mg via intravenous (IV) infusion once every 6 weeks (Q6W) for up to 9 administrations (up to approximately 54 weeks).
干预措施: Belzutifan (Drug)
结局指标
主要结局
Disease-Free Survival (DFS)
时间窗: Up to approximately 54 months
DFS is defined as the time from randomization to the first documented local recurrence, or occurrence of distant kidney cancer metastasis(es) as assessed by investigator, or death due to any cause, whichever occurs first. The DFS for all participants will be presented.
次要结局
- Number of Participants Who Experience at Least One Adverse Event (AE)(Up to approximately 66 weeks)
- Change From Baseline in Health-Related Quality-of-Life (HRQoL) Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 29 and 30 Score(Baseline (Day 1) and up to approximately 36 months)
- Change From Baseline in Physical Functioning Using the EORTC QLQ-C30 Items 1- 5 Score(Baseline (Day 1) and up to approximately 36 months)
- Change From Baseline in Role Functioning Using the EORTC QLQ-C30 Items 6 and 7 Score(Baseline (Day 1) and up to approximately 36 months)
- Change From Baseline in Disease Symptoms Using the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-related Symptoms (FKSI-DRS) Items 1-9 Score(Baseline (Day 1) and up to approximately 36 months)
- Overall Survival (OS)(Up to approximately 89 months)
- Number of Participants Who Discontinue Study Treatment Due to an AE(Up to approximately 54 weeks)
- Disease Recurrence-Specific Survival 1 (DRSS1)(Up to approximately 54 months)
- Disease Recurrence-Specific Survival 2 (DRSS2)(Up to approximately 54 months)